title: Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
abstract: OBJECTIVE
  To evaluate the efficacy of polaprezinc, a mucosal protective agent, in combination with a 7-day triple therapy containing lansoprazole, amoxycillin and clarithromycin, as a treatment for Helicobacter pylori.
  
  
  METHODS
  Sixty-six consecutive patients suffering from dyspeptic symptoms with H. pylori infection were randomly allocated to one of two regimens: one group (LAC; n = 31) received lansoprazole 30 mg b.d., amoxycillin 500 mg b.d. and clarithromycin 400 mg b.d. for 7 days. The other group (LACP; n = 35) received the LAC regimen plus polaprezinc 150 mg b.d. for 7 days. H. pylori status was evaluated by rapid urease test, histology and culture at entry and 4 weeks after treatment.
  
  
  RESULTS
  Five patients did not complete the treatment: no follow-up endoscopy was performed on two patients in the LAC group; one patient in the LAC group and two in the LACP group had their treatment stopped due to severe diarrhoea. By per protocol analysis, H. pylori eradication was achieved in 24 of the 28 evaluable patients (86%; 95% CI: 72-100%) after LAC therapy, and in 33 of the 33 evaluable patients (100%) after LACP therapy (P < 0.05). On intention-to-treat analysis, the rates of eradication were 24 of 31 patients (77%; 95% CI: 62-93%) in the LAC group, and 33 of 35 patients (94%; 95% CI: 86-100%) in the LACP group (P < 0.05).
  
  
  CONCLUSIONS
  A 7-day triple therapy with lansoprazole, amoxycillin and clarithromycin is effective in H. pylori eradication, but this regimen is significantly improved by the addition of polaprezinc.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Institute of Clinical Medicine, IUniversity of Tsukuba, baraki, Japan. hiromasa@md.tsukuba.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Kashimura
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Hassan
authors.forename: K
authors.initials: K
authors.lastname: Ikezawa
authors.forename: T
authors.initials: T
authors.lastname: Sawahata
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Nakahara
authors.forename: H
authors.initials: H
authors.lastname: Mutoh
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002336:Carnosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D020011:Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017967:Zinc Compounds
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D010406:Penicillins; D020011:Protective Agents; D017967:Zinc Compounds; D064747:Lansoprazole; C061957:polaprezinc; D000658:Amoxicillin; D002336:Carnosine; D017291:Clarithromycin; D009853:Omeprazole